Substituted Gamma Lactam Ophthalmic Formulations for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular hypotensive agents, particularly well-defined substituted gamma lactams, face challenges in topical delivery due to poor water solubility, necessitating new formulations for effective treatment of ocular hypertension conditions like glaucoma.
Innovation Solution
Development of ophthalmic formulations containing therapeutically active substituted gamma lactams at specific concentrations in an ophthalmically acceptable liquid vehicle, incorporating buffers, preservatives, tonicity agents, and solubilizers to enhance solubility and stability, allowing for effective topical delivery to the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted gamma lactams are used as ocular hypotensive agents, then treatment efficacy for glaucoma is improved, but water solubility deteriorates making topical delivery difficult
Solution Approach 1:
The patent uses solubilizing agents as intermediaries to bridge the gap between the poorly water-soluble substituted gamma lactams and the aqueous ophthalmic vehicle. These solubilizing agents form microemulsions or micellar structures that encapsulate the hydrophobic drug molecules, allowing them to be delivered topically to the eye while maintaining therapeutic concentrations.
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation system by adjusting pH, ionic strength, and using co-solvents to improve the aqueous solubility of substituted gamma lactams. By modifying these parameters, the formulation achieves both adequate solubility for topical delivery and maintained pharmacological activity.
2Reliability
If concentrated formulations are prepared to ensure therapeutic efficacy, then treatment effectiveness is improved, but solubility requirements increase making formulation difficult
Solution Approach 1:
The patent creates composite ophthalmic formulations that combine substituted gamma lactams with solubilizing agents, buffers, and other excipients in a stable matrix. This composite approach allows the formulation to maintain therapeutic concentrations of the active ingredient while ensuring physical and chemical stability through the synergistic interactions of multiple components.
Solution Approach 2:
The patent employs micellar or liposomal structures where the hydrophobic substituted gamma lactam is nested within the hydrophobic core of micelles or liposomes, while the hydrophilic exterior interacts with the aqueous environment. This nested structure allows high drug loading concentrations while maintaining formulation stability and biocompatibility.
Data Source
AI summary
The invention provides ophthalmic formulations containing well-defined substituted gamma lactams. The formulations described herein are useful in treating a variety of ocular diseases related to ocular hypertension, such as for example, glaucoma.